BioCentury
ARTICLE | Company News

Fleury Medicina e Saude, Veracyte, Sanofi sales and marketing update

May 12, 2014 7:00 AM UTC

Veracyte granted Fleury exclusive rights in Brazil to offer Veracyte's Afirma Gene Expression Classifier when patient's thyroid nodule fine needle aspiration (FNA) samples are indeterminate. Veracyte said its worldwide, co-promotion partner, Sanofi's Genzyme Corp. unit, will promote the Afirma Gene Expression Classifier to physicians throughout Brazil, who will order the test through Fleury. FNA samples will be sent to Veracyte's CLIA-certified laboratory in South San Francisco for analysis. The partners did not disclose financial terms. ...